- Conditions
- Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
- Interventions
- Sitagliptin
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 289
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 13 Years to 25 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fatty Liver
- Interventions
- Cysteamine
- Drug
- Lead sponsor
- Joel Lavine
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Saroglitazar magnesium 1 mg, Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebos
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 18
- States / cities
- Chula Vista, California • Los Angeles, California • Montclair, California + 15 more
- Conditions
- Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Interventions
- Not listed
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Diabetes Prevention Program
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- NAFLD
- Interventions
- Standard of care plus sugar-reduction education
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Interventions
- Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
- Drug · Diagnostic Test · Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
- Interventions
- non-applicable
- Other
- Lead sponsor
- The Geneva Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 826 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Miricorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- NAFLD
- Interventions
- AXA1957, AXA1125, Placebo
- Dietary Supplement
- Lead sponsor
- Axcella Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Lovaza, placebo control
- Drug
- Lead sponsor
- Huntington Medical Research Institutes
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- Hepaxa
- Dietary Supplement
- Lead sponsor
- BASF AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Flowood, Mississippi
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Placebo, PF-06835919
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 86
- States / cities
- Gilbert, Arizona • Tempe, Arizona • Anaheim, California + 50 more
- Conditions
- Hepatic Steatosis
- Interventions
- Low glycemic load diet, Low fat diet
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- NAFLD, NASH
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Maitland, Florida • Monroe, Louisiana • West Monroe, Louisiana + 8 more
- Conditions
- Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Placebo (PB)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Los Angeles, California • Miami, Florida + 2 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Tucson, Arizona
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Resmetirom
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Interventions
- obeticholic acid, placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more